This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GSK586529
Description: GSK586529 is a corticotropin releasing factor R1 (CRF1) receptor antagonist.
Deal Structure: In July 2001, Neurocrine and GSK entered into a worldwide research, development and commercialization agreement for CRF1 receptor antagonists to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression, and IBS.
Partners: Neurocrine Biosciences, Inc.
Additional information available to subscribers only: